BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 38706610)

  • 1. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
    Hagerty BL; Pegna GJ; Xu J; Tai CH; Alewine C
    Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32605175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.
    Skorupan N; Peer CJ; Zhang X; Choo-Wosoba H; Ahmad MI; Lee MJ; Rastogi S; Sato N; Yu Y; Pegna GJ; Steinberg SM; Kalsi SS; Cao L; Figg WD; Trepel JB; Pastan I; FitzGerald D; Alewine C
    Front Oncol; 2024; 14():1386190. PubMed ID: 38706610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
    Hassan R; Alewine C; Mian I; Spreafico A; Siu LL; Gomez-Roca C; Delord JP; Italiano A; Lassen U; Soria JC; Bahleda R; Thomas A; Steinberg SM; Peer CJ; Figg WD; Niederfellner G; Méresse Naegelen V; Pastan I
    Cancer; 2020 Nov; 126(22):4936-4947. PubMed ID: 32870522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.
    Alewine C; Ahmad M; Peer CJ; Hu ZI; Lee MJ; Yuno A; Kindrick JD; Thomas A; Steinberg SM; Trepel JB; Figg WD; Hassan R; Pastan I
    Clin Cancer Res; 2020 Feb; 26(4):828-836. PubMed ID: 31792036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.
    King EM; Mazor R; Çuburu N; Pastan I
    J Immunol; 2018 Mar; 200(6):2038-2045. PubMed ID: 29431691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.
    Mazor R; King E; Pastan I
    Cell Immunol; 2018 Dec; 334():38-41. PubMed ID: 30213644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic developments in pancreatic cancer.
    Hu ZI; O'Reilly EM
    Nat Rev Gastroenterol Hepatol; 2024 Jan; 21(1):7-24. PubMed ID: 37798442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature.
    Kizilocak H; Guerrera MF; Young G
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102194. PubMed ID: 37732158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotorasib in
    Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS
    N Engl J Med; 2023 Jan; 388(1):33-43. PubMed ID: 36546651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures.
    Liu W; Tai CH; Liu X; Pastan I
    Proc Natl Acad Sci U S A; 2022 Nov; 119(48):e2214928119. PubMed ID: 36409889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel.
    Pegna GJ; Lee MJ; Peer CJ; Ahmad MI; Venzon DJ; Yu Y; Yuno A; Steinberg SM; Cao L; Figg WD; Donahue RN; Hassan R; Pastan I; Trepel JB; Alewine C
    Cancer Med; 2023 Feb; 12(4):4236-4249. PubMed ID: 36208017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline
    Yu S; Agarwal P; Mamtani R; Symecko H; Spielman K; O'Hara M; O'Dwyer PJ; Schneider C; Teitelbaum U; Nathanson KL; Domchek SM; Reiss KA
    JCO Precis Oncol; 2019 Dec; 3():1-11. PubMed ID: 35100679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer statistics, 2022.
    Siegel RL; Miller KD; Fuchs HE; Jemal A
    CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.